CLRB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cellectar Biosciences Inc (CLRB) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks strong positive catalysts, has weak financial performance, and no significant trading signals or recent news to support a bullish case. Additionally, technical indicators and options data do not suggest a favorable entry point.
The MACD histogram is negative and expanding (-0.0123), indicating bearish momentum. RSI is neutral at 30.124, showing no clear signal. Moving averages are converging, suggesting indecision in price direction. Support is at 2.947, with resistance at 3.375. The stock has a 40% chance to decline further in the next week and month.
Maxim upgraded the stock to Buy with a $10 price target. The FDA and Cellectar defined a regulatory path for iopofosine, which could be a long-term positive catalyst.
Roth Capital lowered the price target from $18 to $14 due to model adjustments. The company's financials show no revenue, negative net income (-$5.3M), and declining EPS (-23.21% YoY). No recent news or significant insider/hedge fund activity.
In Q4 2025, revenue remained at $0 with no growth. Net income improved YoY by 124.81% but is still negative (-$5.3M). EPS dropped by -23.21% YoY to -1.29. Gross margin remains at 0%. Overall, the financials are weak and do not support a strong investment case.
Maxim upgraded the stock to Buy with a $10 price target. Roth Capital maintained a Buy rating but lowered the price target to $14 from $18 due to model adjustments. Analysts remain cautiously optimistic but with reduced expectations.
